Wilms Tumor.
This record reviews Wilms tumor biology, risk stratification, and multimodal treatment, contrasting upfront nephrectomy with preoperative chemotherapy and highlighting nephron-sparing surgery, intensified treatment for high-risk disease, and trials seeking toxicity reduction.
Open original publication →What the AI sees
This record reviews Wilms tumor biology, risk stratification, and multimodal treatment, contrasting upfront nephrectomy with preoperative chemotherapy and highlighting nephron-sparing surgery, intensified treatment for high-risk disease, and trials seeking toxicity reduction.
Research significance
The supplied record supports current risk-adapted, multimodal management of Wilms tumor; it is reasonable but inferential to hypothesize that biomarker-refined treatment selection and de-escalation trials could preserve cure rates while reducing toxicity, because no trial outcomes or comparative data are provided.
Source abstract
Wilms tumor (WT) is the most common pediatric renal malignancy, characterized by triphasic histology and strong links to disrupted kidney development. Advances in molecular profiling and international collaboration have refined risk stratification using histology, stage, and biomarkers. Treatment combines surgery, chemotherapy, and radiation, with protocol differences between Children's Oncology Group (upfront nephrectomy) and International Society of Pediatric Oncology (preoperative chemotherapy). Nephron-sparing surgery is prioritized for bilateral disease to preserve renal function. Despite excellent survival for favorable histology WT, diffuse anaplasia and adverse molecular features require intensified therapy. Emerging trials aim to reduce toxicity while maintaining cure rates.